Vivos Therapeutics Stock Alpha and Beta Analysis
| VVOS Stock | USD 4.52 0.06 1.35% |
This module allows you to check different measures of market premium (i.e., alpha and beta) for all equities such as Vivos Therapeutics. It also helps investors analyze the systematic and unsystematic risks associated with investing in Vivos Therapeutics over a specified time horizon. Remember, high Vivos Therapeutics' alpha is almost always a sign of good performance; however, a high beta will depend on investors' risk tolerance level and may signal increased volatility and potential future overvaluation. Key technical indicators related to Vivos Therapeutics' market risk premium analysis include:
Beta 1.17 | Alpha 0.88 | Risk 7.24 | Sharpe Ratio 0.15 | Expected Return 1.08 |
Enterprise Value |
|
Alpha is a measure of relative performance on a risk-adjusted basis, while beta measures volatility against the benchmark. The goal is to know if an investor is being compensated for the volatility risk taken. The return on investment might be better than its reference but still not compensate for the assumption of the risk.
Check out Vivos Therapeutics Backtesting, Vivos Therapeutics Valuation, Vivos Therapeutics Correlation, Vivos Therapeutics Hype Analysis, Vivos Therapeutics Volatility, Vivos Therapeutics History and analyze Vivos Therapeutics Performance. Vivos Therapeutics Market Premiums
Investors always prefer to have the highest possible return on investment, coupled with the lowest possible volatility. Vivos Therapeutics market risk premium is the additional return an investor will receive from holding Vivos Therapeutics long position in a well-diversified portfolio. The market premium is part of the Capital Asset Pricing Model (CAPM), which most analysts and investors use to calculate the acceptable rate of return on investment in Vivos Therapeutics. At the center of the CAPM is the concept of risk and reward, which is usually communicated by investors using alpha and beta measures. Alpha and beta are two of the key measurements used to evaluate Vivos Therapeutics' performance over market.| α | 0.88 | β | 1.17 |
Vivos Therapeutics expected buy-and-hold returns
Although buy-and-hold investment strategy may not appeal to all investors, it may be used as a good measure of Vivos Therapeutics' Buy-and-hold return. Our buy-and-hold chart shows how Vivos Therapeutics performed over your current time horizon against a typical interest-earning bank account and a selected benchmark.Vivos Therapeutics Market Price Analysis
Market price analysis indicators help investors to evaluate how Vivos Therapeutics stock reacts to ongoing and evolving market conditions. The investors can use it to make informed decisions about market timing, and determine when trading Vivos Therapeutics shares will generate the highest return on investment. By understating and applying Vivos Therapeutics stock market price indicators, traders can identify Vivos Therapeutics position entry and exit signals to maximize returns.
Vivos Therapeutics Return and Market Media
The median price of Vivos Therapeutics for the period between Fri, May 2, 2025 and Thu, Jul 31, 2025 is 2.84 with a coefficient of variation of 42.08. The daily time series for the period is distributed with a sample standard deviation of 1.47, arithmetic mean of 3.49, and mean deviation of 1.24. The Stock received substential amount of media coverage during this period. Price Growth (%) |
| Timeline |
1 | Vivos Therapeutics Stock Rating Lowered by Alliance Global Partners | 05/23/2025 |
2 | Insider Trading | 06/09/2025 |
3 | Vivos Therapeutics Completes Acquisition of Nevada Sleep Center VVOS Stock News | 06/11/2025 |
4 | SP Manager LLC Intends to Engage with Vivos Therapeutics, Inc. - MarketScreener | 06/17/2025 |
5 | Vivos Therapeutics Device Shows Promise for Pediatric Sleep Apnea VVOS Stock News | 06/26/2025 |
6 | Vivos Therapeutics Receives Medicare Approval for VidaSleep Ora | 07/01/2025 |
7 | Is Vivos Therapeutics Inc. a good long term investment - Rapid capital growth - Jammu Links News | 07/18/2025 |
8 | What analysts say about Vivos Therapeutics Inc. stock - Massive portfolio appreciation - jammulinksnews.com | 07/22/2025 |
9 | Is Vivos Therapeutics Inc. stock a growth or value play - High-profit capital plays - jammulinksnews.com | 07/25/2025 |
10 | Vivos Therapeutics Adds to Management Teamto Support Expansion and Growth | 07/30/2025 |
About Vivos Therapeutics Beta and Alpha
For many years both, Alpha and Beta indicators are used by professional money managers as critical performance measurement tools across virtually all financial instruments including Vivos or other stocks. Alpha measures the amount that position in Vivos Therapeutics has returned in comparison to a selected market index or another relevant benchmark. In other words, Alpha is the excess return on an investment relative to the performance of your selected benchmark. Beta, on the other hand, measures the relative risk of your investment.
| 2024 | 2025 (projected) | Payables Turnover | 5.48 | 2.88 | Days Of Inventory On Hand | 31.67 | 28.15 |
Vivos Therapeutics Upcoming Company Events
As portrayed in its financial statements, the presentation of Vivos Therapeutics' financial position is often influenced by management's estimates, judgments, and sometimes even manipulations. In the best case, Vivos Therapeutics' leadership is honest, while the outside auditors are strict and uncompromising. Whatever the case, investors should always follow all of Vivos Therapeutics' public filing events to personally review all filings and be reasonable and skeptical to interpret all of the financial statements of Vivos Therapeutics. Please utilize our Beneish M Score to check the likelihood of Vivos Therapeutics' management manipulating its earnings.
| 4th of April 2024 Upcoming Quarterly Report | View | |
| 31st of December 2023 Next Fiscal Quarter End | View | |
| 30th of September 2023 Last Quarter Report | View |
Build Portfolio with Vivos Therapeutics
Your optimized portfolios are the building block of your wealth. We provide an intuitive interface to determine which securities in a portfolio should be removed or rebalanced to achieve better diversification, find the right mix of securities that minimizes portfolio risk for a given return, or maximize portfolio expected return for a given risk level.Build Diversified Portfolios
Align your risk with return expectations
Additional Tools for Vivos Stock Analysis
When running Vivos Therapeutics' price analysis, check to measure Vivos Therapeutics' market volatility, profitability, liquidity, solvency, efficiency, growth potential, financial leverage, and other vital indicators. We have many different tools that can be utilized to determine how healthy Vivos Therapeutics is operating at the current time. Most of Vivos Therapeutics' value examination focuses on studying past and present price action to predict the probability of Vivos Therapeutics' future price movements. You can analyze the entity against its peers and the financial market as a whole to determine factors that move Vivos Therapeutics' price. Additionally, you may evaluate how the addition of Vivos Therapeutics to your portfolios can decrease your overall portfolio volatility.